Intervention against the Maillard reaction in vivo
The field of Maillard/glycation reactions in vivo has grown enormously during the past 20 years, going from 25 to 500 publications per year. It is now well recognized that many of the “advanced” products form oxidatively or anaerobically and can have deleterious effects on macromolecular and biologi...
Gespeichert in:
| Veröffentlicht in: | Archives of biochemistry and biophysics 2003-11, Vol.419 (1), p.1-15 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 15 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Archives of biochemistry and biophysics |
| container_volume | 419 |
| creator | Monnier, Vincent M. |
| description | The field of Maillard/glycation reactions in vivo has grown enormously during the past 20 years, going from 25 to 500 publications per year. It is now well recognized that many of the “advanced” products form oxidatively or anaerobically and can have deleterious effects on macromolecular and biological function. The feasibility of developing pharmacological agents with beneficial in vivo properties, based on in vitro inhibition of glycation, has been surprisingly successful. This Editorial sets the stage for a series of articles by experts in the field, who have made key contributions to our understanding of the Maillard reaction in vivo. |
| doi_str_mv | 10.1016/j.abb.2003.08.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71291340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003986103004363</els_id><sourcerecordid>71291340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-274bda45df05c15faf7bfda74912c7825e06f2689df3e37386aa4e5ff0f0b6673</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwA1hQJraEs-M4jpgQ4qNSEQvMlmOfwVWbFDuNxL_HpZXYmG54n3t19xBySaGgQMXNstBtWzCAsgBZAOVHZEqhETmUkh-TKaQkb6SgE3IW4xKAUi7YKZlQXgmZwilh827AMGI3-L7L9If2XRyy4ROzF-1XKx1sFlCb39R32ejH_pycOL2KeHGYM_L--PB2_5wvXp_m93eL3HBaDTmreWs1r6yDytDKaVe3zuqaN5SZWrIKQTgmZGNdiWVdSqE1x8o5cNAKUZczcr3v3YT-a4txUGsfDaajOuy3UdWUNbTkkEC6B03oYwzo1Cb4tQ7fioLaiVJLlUSpnSgFUiVRaefqUL5t12j_Ng5mEnC7BzC9OHoMKhqPnUHrA5pB2d7_U_8Drd935g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71291340</pqid></control><display><type>article</type><title>Intervention against the Maillard reaction in vivo</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Monnier, Vincent M.</creator><creatorcontrib>Monnier, Vincent M.</creatorcontrib><description>The field of Maillard/glycation reactions in vivo has grown enormously during the past 20 years, going from 25 to 500 publications per year. It is now well recognized that many of the “advanced” products form oxidatively or anaerobically and can have deleterious effects on macromolecular and biological function. The feasibility of developing pharmacological agents with beneficial in vivo properties, based on in vitro inhibition of glycation, has been surprisingly successful. This Editorial sets the stage for a series of articles by experts in the field, who have made key contributions to our understanding of the Maillard reaction in vivo.</description><identifier>ISSN: 0003-9861</identifier><identifier>EISSN: 1096-0384</identifier><identifier>DOI: 10.1016/j.abb.2003.08.014</identifier><identifier>PMID: 14568003</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aging ; Aging - metabolism ; Animals ; Diabetes ; Diabetes Complications ; Diabetes Mellitus - metabolism ; End stage renal disease ; Glycation ; Glycation End Products, Advanced - antagonists & inhibitors ; Glycation End Products, Advanced - metabolism ; Humans ; Inflammation ; Inflammation - metabolism ; Kidney Failure, Chronic - metabolism ; Maillard Reaction ; Oxidation ; Oxidation-Reduction</subject><ispartof>Archives of biochemistry and biophysics, 2003-11, Vol.419 (1), p.1-15</ispartof><rights>2003 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-274bda45df05c15faf7bfda74912c7825e06f2689df3e37386aa4e5ff0f0b6673</citedby><cites>FETCH-LOGICAL-c415t-274bda45df05c15faf7bfda74912c7825e06f2689df3e37386aa4e5ff0f0b6673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.abb.2003.08.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14568003$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Monnier, Vincent M.</creatorcontrib><title>Intervention against the Maillard reaction in vivo</title><title>Archives of biochemistry and biophysics</title><addtitle>Arch Biochem Biophys</addtitle><description>The field of Maillard/glycation reactions in vivo has grown enormously during the past 20 years, going from 25 to 500 publications per year. It is now well recognized that many of the “advanced” products form oxidatively or anaerobically and can have deleterious effects on macromolecular and biological function. The feasibility of developing pharmacological agents with beneficial in vivo properties, based on in vitro inhibition of glycation, has been surprisingly successful. This Editorial sets the stage for a series of articles by experts in the field, who have made key contributions to our understanding of the Maillard reaction in vivo.</description><subject>Aging</subject><subject>Aging - metabolism</subject><subject>Animals</subject><subject>Diabetes</subject><subject>Diabetes Complications</subject><subject>Diabetes Mellitus - metabolism</subject><subject>End stage renal disease</subject><subject>Glycation</subject><subject>Glycation End Products, Advanced - antagonists & inhibitors</subject><subject>Glycation End Products, Advanced - metabolism</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - metabolism</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>Maillard Reaction</subject><subject>Oxidation</subject><subject>Oxidation-Reduction</subject><issn>0003-9861</issn><issn>1096-0384</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwA1hQJraEs-M4jpgQ4qNSEQvMlmOfwVWbFDuNxL_HpZXYmG54n3t19xBySaGgQMXNstBtWzCAsgBZAOVHZEqhETmUkh-TKaQkb6SgE3IW4xKAUi7YKZlQXgmZwilh827AMGI3-L7L9If2XRyy4ROzF-1XKx1sFlCb39R32ejH_pycOL2KeHGYM_L--PB2_5wvXp_m93eL3HBaDTmreWs1r6yDytDKaVe3zuqaN5SZWrIKQTgmZGNdiWVdSqE1x8o5cNAKUZczcr3v3YT-a4txUGsfDaajOuy3UdWUNbTkkEC6B03oYwzo1Cb4tQ7fioLaiVJLlUSpnSgFUiVRaefqUL5t12j_Ng5mEnC7BzC9OHoMKhqPnUHrA5pB2d7_U_8Drd935g</recordid><startdate>20031101</startdate><enddate>20031101</enddate><creator>Monnier, Vincent M.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031101</creationdate><title>Intervention against the Maillard reaction in vivo</title><author>Monnier, Vincent M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-274bda45df05c15faf7bfda74912c7825e06f2689df3e37386aa4e5ff0f0b6673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Aging</topic><topic>Aging - metabolism</topic><topic>Animals</topic><topic>Diabetes</topic><topic>Diabetes Complications</topic><topic>Diabetes Mellitus - metabolism</topic><topic>End stage renal disease</topic><topic>Glycation</topic><topic>Glycation End Products, Advanced - antagonists & inhibitors</topic><topic>Glycation End Products, Advanced - metabolism</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - metabolism</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>Maillard Reaction</topic><topic>Oxidation</topic><topic>Oxidation-Reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Monnier, Vincent M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of biochemistry and biophysics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Monnier, Vincent M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intervention against the Maillard reaction in vivo</atitle><jtitle>Archives of biochemistry and biophysics</jtitle><addtitle>Arch Biochem Biophys</addtitle><date>2003-11-01</date><risdate>2003</risdate><volume>419</volume><issue>1</issue><spage>1</spage><epage>15</epage><pages>1-15</pages><issn>0003-9861</issn><eissn>1096-0384</eissn><abstract>The field of Maillard/glycation reactions in vivo has grown enormously during the past 20 years, going from 25 to 500 publications per year. It is now well recognized that many of the “advanced” products form oxidatively or anaerobically and can have deleterious effects on macromolecular and biological function. The feasibility of developing pharmacological agents with beneficial in vivo properties, based on in vitro inhibition of glycation, has been surprisingly successful. This Editorial sets the stage for a series of articles by experts in the field, who have made key contributions to our understanding of the Maillard reaction in vivo.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>14568003</pmid><doi>10.1016/j.abb.2003.08.014</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-9861 |
| ispartof | Archives of biochemistry and biophysics, 2003-11, Vol.419 (1), p.1-15 |
| issn | 0003-9861 1096-0384 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71291340 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aging Aging - metabolism Animals Diabetes Diabetes Complications Diabetes Mellitus - metabolism End stage renal disease Glycation Glycation End Products, Advanced - antagonists & inhibitors Glycation End Products, Advanced - metabolism Humans Inflammation Inflammation - metabolism Kidney Failure, Chronic - metabolism Maillard Reaction Oxidation Oxidation-Reduction |
| title | Intervention against the Maillard reaction in vivo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A12%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intervention%20against%20the%20Maillard%20reaction%20in%20vivo&rft.jtitle=Archives%20of%20biochemistry%20and%20biophysics&rft.au=Monnier,%20Vincent%20M.&rft.date=2003-11-01&rft.volume=419&rft.issue=1&rft.spage=1&rft.epage=15&rft.pages=1-15&rft.issn=0003-9861&rft.eissn=1096-0384&rft_id=info:doi/10.1016/j.abb.2003.08.014&rft_dat=%3Cproquest_cross%3E71291340%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71291340&rft_id=info:pmid/14568003&rft_els_id=S0003986103004363&rfr_iscdi=true |